Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial
Authors:
Open Access
- 20 September 2020
- journal article
- research article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 9 (4) , 913-926
Abstract
Introduction Coronavirus disease 2019 (COVID-19) is a viral respiratory syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus was discovered in Wuhan City, Hubei Province, China, in December 2019. As of September 6, 2020, confirmed cases have risen to more than 27,000,000 worldwide and more than 885,000 people have died. Currently, no cure or standard treatment for COVID-19 exists. We conducted a prospective single-arm open-label phase II clinical trial assessing the safety and efficacy of convalescent plasma in hospitalized patients with COVID-19. Methods Convalescent plasma with sufficient total anti-SARS-CoV-2 IgG titer (1:320) obtained from recovered donors was administered to adult patients with either severe or critical COVID-19 illness. Primary outcomes were adverse events in association with plasma administration, and hospital mortality. Secondary outcomes included disease progression, recovery, length of stay, and hospital discharge. Results Of the 38 patients included in the analysis, 24 (63%) recovered and were discharged, and 14 (37%) died. Patients who received convalescent plasma early in the disease course (severe illness group) as compared to the patients that received convalescent plasma later in the disease progression (critical illness group) had significantly lower hospital mortality 13% vs 55% (p < 0.02) and shorter mean hospital length of stay 15.4 vs 33 days (p < 0.01). One patient experienced a transient transfusion reaction. No other adverse effects of convalescent plasma infusion were observed. Conclusions Our results suggest that convalescent plasma with adequate anti-SARS-CoV-2 antibody titer is safe and has the potential for positive impact on clinical outcomes including recovery and survival if given to patients early in the course of COVID-19 disease. Trial Registration ClinicalTrials.gov. Identifier, NCT04343261, IND #19805.Keywords
All Related Versions
Funding Information
- Trinity Health of New England
This publication has 33 references indexed in Scilit:
- Clinical progression of patients with COVID-19 in Shanghai, ChinaJournal of Infection, 2020
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent PlasmaJAMA, 2020
- Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19Aging, 2020
- Effectiveness of convalescent plasma therapy in severe COVID-19 patientsProceedings of the National Academy of Sciences, 2020
- A New Symptom of COVID‐19: Loss of Taste and SmellObesity, 2020
- A Systematic Review of COVID-19 Epidemiology Based on Current EvidenceJournal of Clinical Medicine, 2020
- Clinical and immunological features of severe and moderate coronavirus disease 2019Journal of Clinical Investigation, 2020
- Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective studyChinese Medical Journal, 2020
- Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus diseaseChinese Medical Journal, 2020
- The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysisThe Journal of Infectious Diseases, 2014